Aktis Oncology (NASDAQ:AKTS) Given Average Recommendation of “Buy” by Analysts

Aktis Oncology (NASDAQ:AKTS) has earned a consensus rating of “Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $31.25.

Several analysts have recently issued reports on AKTS shares. TD Cowen began coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating for the company. JPMorgan Chase & Co. assumed coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective on the stock. Bank of America initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price for the company. HC Wainwright began coverage on Aktis Oncology in a report on Monday. They set a “buy” rating and a $30.00 target price for the company. Finally, Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th.

Aktis Oncology Price Performance

NASDAQ AKTS opened at $18.81 on Monday. Aktis Oncology has a 52-week low of $16.80 and a 52-week high of $29.16.

Insider Transactions at Aktis Oncology

In related news, major shareholder Vida Ventures Ii, Llc purchased 835,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the acquisition, the insider directly owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. This represents a 17.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ecor1 Capital, Llc acquired 2,222,222 shares of the stock in a transaction dated Monday, January 12th. The shares were bought at an average price of $18.00 per share, for a total transaction of $39,999,996.00. Following the transaction, the director owned 4,348,658 shares in the company, valued at approximately $78,275,844. This represents a 104.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 6,117,776 shares of company stock worth $110,119,968. 3.30% of the stock is owned by insiders.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.